EGFR Clinical Trials in Beijing, Beijing Municipality
6 recruitingBeijing, Beijing Municipality, China
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
HER2 MutationAdvanced Non-Small Cell Lung CancerEGFR Mutation
Bayer400 enrolled94 locationsNCT05099172
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 3
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR
Allist Pharmaceuticals, Inc.300 enrolled2 locationsNCT06956001
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
Phase 1Phase 2
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.100 enrolled12 locationsNCT06631989
Recruiting
Phase 2
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NSCLCBrain MetastasesEGFR Activating Mutation
TYK Medicines, Inc420 enrolled1 locationNCT05948813